Doudna, J. A. The promise and challenge of therapeutic genome editing. Nature 578, 229–236 (2020).
Pacesa, M., Pelea, O. & Jinek, M. Past, present, and future of CRISPR genome editing technologies. Cell 187, 1076–1100 (2024).
Zhong, G. et al. A reversible RNA on-switch that controls gene expression of AAV-delivered therapeutics in vivo. Nat. Biotechnol. 38, 169–175 (2020).
Monteys, A. M. et al. Regulated control of gene therapies by drug-induced splicing. Nature 596, 291–295 (2021).
Liu, R. et al. Optogenetic control of RNA function and metabolism using engineered light-switchable RNA-binding proteins. Nat. Biotechnol. 40, 779–786 (2022).
Pfeiffer, L. S. & Stafforst, T. Precision RNA base editing with engineered and endogenous effectors. Nat. Biotechnol. 41, 1526–1542 (2023).
Booth, B. J. et al. RNA editing: expanding the potential of RNA therapeutics. Mol. Ther. 31, 1533–1549 (2023).
Song, J., Zhuang, Y. & Yi, C. Programmable RNA base editing via targeted modifications. Nat. Chem. Biol. 20, 277–290 (2024).
Merkle, T. et al. Precise RNA editing by recruiting endogenous ADARs with antisense oligonucleotides. Nat. Biotechnol. 37, 133–138 (2019).
Qu, L. et al. Programmable RNA editing by recruiting endogenous ADAR using engineered RNAs. Nat. Biotechnol. 37, 1059–1069 (2019).
Reautschnig, P. et al. CLUSTER guide RNAs enable precise and efficient RNA editing with endogenous ADAR enzymes in vivo. Nat. Biotechnol. 40, 759–768 (2022).
Katrekar, D. et al. Efficient in vitro and in vivo RNA editing via recruitment of endogenous ADARs using circular guide RNAs. Nat. Biotechnol. 40, 938–945 (2022).
Vogel, P. et al. Efficient and precise editing of endogenous transcripts with SNAP-tagged ADARs. Nat. Methods 15, 535–538 (2018).
Montiel-Gonzalez, M. F., Vallecillo-Viejo, I., Yudowski, G. A. & Rosenthal, J. J. C. Correction of mutations within the cystic fibrosis transmembrane conductance regulator by site-directed RNA editing. Proc. Natl Acad. Sci. USA 110, 18285–18290 (2013).
Han, W. et al. Programmable RNA base editing with a single gRNA-free enzyme. Nucleic Acids Res. 50, 9580–9595 (2022).
Cox, D. B. T. et al. RNA editing with CRISPR-Cas13. Science 358, 1019–1027 (2017).
Kannan, S. et al. Compact RNA editors with small Cas13 proteins. Nat. Biotechnol. 40, 194–197 (2022).
Xu, C. et al. Programmable RNA editing with compact CRISPR–Cas13 systems from uncultivated microbes. Nat. Methods 18, 499–506 (2021).
Rauch, S. et al. Programmable RNA-guided RNA effector proteins built from human parts. Cell 178, 122–134.e12 (2019).
Rauch, S., Jones, K. A. & Dickinson, B. C. Small molecule-inducible RNA-targeting systems for temporal control of RNA regulation. ACS Cent. Sci. 6, 1987–1996 (2020).
Stroppel, A. S., Lappalainen, R. & Stafforst, T. Controlling site-directed RNA editing by chemically induced dimerization. Chemistry 27, 12300–12304 (2021).
Zhang, Y. et al. Light-triggered site-directed RNA editing by endogenous ADAR1 with photolabile guide RNA. Cell Chem. Biol. 30, 672–682.e5 (2023).
Hanswillemenke, A., Kuzdere, T., Vogel, P., Jékely, G. & Stafforst, T. Site-directed RNA editing in vivo can be triggered by the light-driven assembly of an artificial riboprotein. J. Am. Chem. Soc. 137, 15875–15881 (2015).
Bennett, C. F., Baker, B. F., Pham, N., Swayze, E. & Geary, R. S. Pharmacology of antisense drugs. Annu. Rev. Pharmacol. Toxicol. 57, 81–105 (2017).
Yu, J. et al. Programmable RNA base editing with photoactivatable CRISPR-Cas13. Nat. Commun. 15, 673 (2024).
Kawano, F., Suzuki, H., Furuya, A. & Sato, M. Engineered pairs of distinct photoswitches for optogenetic control of cellular proteins. Nat. Commun. 6, 6256 (2015).
Katrekar, D. et al. Comprehensive interrogation of the ADAR2 deaminase domain for engineering enhanced RNA editing activity and specificity. Elife 11, 1–19 (2022).
Wong, S. K., Sato, S. & Lazinski, D. W. Substrate recognition by ADAR1 and ADAR2. RNA 7, 846–858 (2001).
Konermann, S. et al. Transcriptome engineering with RNA-targeting type VI-D CRISPR effectors. Cell 173, 665–676.e14 (2018).
Paulmurugan, R. & Gambhir, S. S. Combinatorial library screening for developing an improved split-firefly luciferase fragment-assisted complementation system for studying protein–protein interactions. Anal. Chem. 79, 2346–2353 (2007).
Li, H. et al. Efficient photoactivatable Dre recombinase for cell type-specific spatiotemporal control of genome engineering in the mouse. Proc. Natl Acad. Sci. USA 117, 33426–33435 (2020).
Li, H. et al. Stable transgenic mouse strain with enhanced photoactivatable Cre recombinase for spatiotemporal genome manipulation. Adv. Sci. 9, 1–12 (2022).
Kuttan, A. & Bass, B. L. Mechanistic insights into editing-site specificity of ADARs. Proc. Natl Acad. Sci. USA 109, E3295–E3304 (2012).
Wang, X. et al. Develop a compact RNA base editor by fusing ADAR with engineered EcCas6e. Adv. Sci. 10, 1–8 (2023).
Benedetti, L. et al. Optimized vivid-derived magnets photodimerizers for subcellular optogenetics in mammalian cells. Elife 9, 1–49 (2020).
Martins-Dias, P. & Romão, L. Nonsense suppression therapies in human genetic diseases. Cell. Mol. Life Sci. 78, 4677–4701 (2021).
Luo, N. et al. Near-cognate tRNAs increase the efficiency and precision of pseudouridine-mediated readthrough of premature termination codons. Nat. Biotechnol. 43, 114–123 (2025).
Albers, S. et al. Engineered tRNAs suppress nonsense mutations in cells and in vivo. Nature 618, 842–848 (2023).
Yi, Z. et al. Engineered circular ADAR-recruiting RNAs increase the efficiency and fidelity of RNA editing in vitro and in vivo. Nat. Biotechnol. 40, 946–955 (2022).
MacDonald, B. T., Tamai, K. & He, X. Wnt/β-catenin signaling: components, mechanisms, and diseases. Dev. Cell 17, 9–26 (2009).
Liu, C. et al. Control of β-catenin phosphorylation/degradation by a dual-kinase mechanism. Cell 108, 837–847 (2002).
Kay, M. A., He, C.-Y. & Chen, Z.-Y. A robust system for production of minicircle DNA vectors. Nat. Biotechnol. 28, 1287–1289 (2010).
Lamb, Y. N. & Hoy, S. M. Eftrenonacog alfa: a review in haemophilia B. Drugs 83, 807–818 (2023).
Nathwani, A. C. et al. Long-term safety and efficacy of factor IX gene therapy in hemophilia B. N. Engl. J. Med. 371, 1994–2004 (2014).
George, L. A. et al. Hemophilia B gene therapy with a high-specific-activity factor IX variant. N. Engl. J. Med. 377, 2215–2227 (2017).
Kaczmarek, R. & Herzog, R. W. Treatment-induced hemophilic thrombosis? Mol. Ther. 30, 505–506 (2022).
Simioni, P. et al. X-linked thrombophilia with a mutant factor IX (factor IX Padua). N. Engl. J. Med. 361, 1671–1675 (2009).
Guan, Y. et al. CRISPR/Cas9‐mediated somatic correction of a novel coagulator factor IX gene mutation ameliorates hemophilia in mouse. EMBO Mol. Med. 8, 477–488 (2016).
Anadón, C. et al. Gene amplification-associated overexpression of the RNA editing enzyme ADAR1 enhances human lung tumorigenesis. Oncogene 35, 4407–4413 (2016).
Teoh, P. J. et al. Aberrant hyperediting of the myeloma transcriptome by ADAR1 confers oncogenicity and is a marker of poor prognosis. Blood 132, 1304–1317 (2018).
Nguyen, N. T. et al. Nano-optogenetic engineering of CAR T cells for precision immunotherapy with enhanced safety. Nat. Nanotechnol. 16, 1424–1434 (2021).
Huang, Z. et al. Engineering light-controllable CAR T cells for cancer immunotherapy. Sci. Adv. 6, 1–14 (2020).
Bansal, A., Shikha, S. & Zhang, Y. Towards translational optogenetics. Nat. Biomed. Eng. 7, 349–369 (2023).
Zhou, Y. et al. A small and highly sensitive red/far-red optogenetic switch for applications in mammals. Nat. Biotechnol. 40, 262–272 (2022).
Kuwasaki, Y. et al. A red light-responsive photoswitch for deep tissue optogenetics. Nat. Biotechnol. 40, 1672–1679 (2022).
Bonger, K. M., Chen, L., Liu, C. W. & Wandless, T. J. Small-molecule displacement of a cryptic degron causes conditional protein degradation. Nat. Chem. Biol. 7, 531–537 (2011).
Hwang, G.-H. et al. Web-based design and analysis tools for CRISPR base editing. BMC Bioinformatics 19, 542 (2018).
Li, H. et al. Engineering a photoactivatable A-to-I RNA base editor for gene therapy in vivo. NCBI SRA https://www.ncbi.nlm.nih.gov/bioproject/PRJNA1194220 (2025).
Li, H. et al. Engineering a photoactivatable A-to-I RNA base editor for gene therapy in vivo. NCBI SRA https://www.ncbi.nlm.nih.gov/bioproject/PRJNA1194292 (2025).
Li, H. et al. Engineering a photoactivatable A-to-I RNA base editor for gene therapy in vivo. NCBI SRA https://www.ncbi.nlm.nih.gov/bioproject/PRJNA1197542 (2025).
Li, H. et al. Engineering a photoactivatable A-to-I RNA base editor for gene therapy in vivo. NCBI SRA https://www.ncbi.nlm.nih.gov/bioproject/PRJNA1207784 (2025).
Li, H. et al. Engineering a photoactivatable A-to-I RNA base editor for gene therapy in vivo. NCBI SRA https://www.ncbi.nlm.nih.gov/bioproject/PRJNA1194549 (2025).
Li, H. et al. Engineering a photoactivatable A-to-I RNA base editor for gene therapy in vivo. NCBI SRA https://www.ncbi.nlm.nih.gov/bioproject/PRJNA1207789 (2025).
